Nicholas J. Lawrence

Nicholas J. Lawrence

Auto-generated profile, based on publicly available information

Nicholas J. Lawrence

Dep. Chem., Univ. Manchester Inst. Sci. Technol., Manchester M60 1QD, UK

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HLHarshani R. Lawrence
Harshani R. Lawrence
RPRoberta Pireddu
Roberta Pireddu
LCLiwei Chen
Liwei Chen
YLYunting Luo
Yunting Luo
SSShen-Shu Sung
Shen-Shu Sung
NLNicholas J. Lawrence
Nicholas J. Lawrence

30 August 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HLHarshani R. Lawrence
Harshani R. Lawrence
MMMathew P. Martin
Mathew P. Martin
YLYunting Luo
Yunting Luo
RPRoberta Pireddu
Roberta Pireddu
HYHua Yang
Hua Yang
NLNicholas J. Lawrence
Nicholas J. Lawrence

1 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJeremy J. McGuire
Jeremy J. McGuire
JFJeremy Frieling
Jeremy Frieling
CLChen Hao Lo
Chen Hao Lo
TLTao Li
Tao Li
AMAyaz Muhammad
Ayaz Muhammad
CLConor C Lynch
Conor C Lynch
Bone metastatic prostate cancer (PCa) promotes mesenchymal stem cell (MSC) recruitment and their differentiation into osteoblasts. However, the effects of bone-marrow derived MSCs on PCa cells are less explored. Here, we report MSC-derived interleukin-28 (IL-28) triggers prostate cancer cell apoptosis via IL-28 receptor alpha (IL-28Rα)-STAT1 signaling. However, chronic exposure to MSCs drives the selection of prostate cancer cells that are resistant to IL-28-induced apoptosis and therapeutics such as docetaxel. Further, MSC-selected/IL-28-resistant prostate cancer cells grow at accelerated rates in bone. Acquired resistance to apoptosis is PCa cell intrinsic, and is associated with a shift in IL-28Rα signaling via STAT1 to STAT3. Notably, STAT3 ablation or inhibition impairs MSC-selected prostate cancer cell growth and survival. Thus, bone marrow MSCs drive the emergence of therapy-resistant bone metastatic prostate cancer yet this can be disabled by targeting STAT3.

1 June 2017 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
SEStuart W. Ember
Stuart W. Ember
QLQue T. Lambert
Que T. Lambert
NBNorbert Berndt
Norbert Berndt
SGSteven Gunawan
Steven Gunawan
MAMuhammad Ayaz
Muhammad Ayaz
ESErnst Schonbrunn
Ernst Schonbrunn
Synergistic action of kinase and BET bromodomain inhibitors in cell killing has been reported for a variety of cancers. Using the chemical scaffold of the JAK2 inhibitor TG101348, we developed and characterized single agents which potently and simultaneously inhibit BRD4 and a specific set of oncogenic tyrosine kinases including JAK2, FLT3, RET, and ROS1. Lead compounds showed on-target inhibition in several blood cancer cell lines and were highly efficacious at inhibiting the growth of hematopoietic progenitor cells from patients with myeloproliferative neoplasm. Screening across 931 cancer cell lines revealed differential growth inhibitory potential with highest activity against bone and blood cancers and greatly enhanced activity over the single BET inhibitor JQ1. Gene drug sensitivity analyses and drug combination studies indicate synergism of BRD4 and kinase inhibition as a plausible reason for the superior potency in cell killing. Combined, our findings indicate promising potential of these agents as novel chemical probes and cancer therapeutics. Mol Cancer Ther; 16(6); 1054–67. ©2017 AACR.

20 February 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HLHarshani R. Lawrence
Harshani R. Lawrence
KMKiran Mahajan
Kiran Mahajan
YLYunting Luo
Yunting Luo
DZDaniel Zhang
Daniel Zhang
NTNathan Tindall
Nathan Tindall
NLNicholas J. Lawrence
Nicholas J. Lawrence

1 January 2011 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
LSLatanya M. Scott
Latanya M. Scott
LCLiwei Chen
Liwei Chen
KDKenyon G. Daniel
Kenyon G. Daniel
WBWesley Brooks
Wesley Brooks
WGWayne C. Guida
Wayne C. Guida
JWJie Wu
Jie Wu